1 Key Insights

2 Report Introduction

3 Chronic Lower Back Pain (CLBP) Market Overview at a Glance

3.1 Market Share (%) Distribution of CLBP by Therapies in 2020

3.2 Market Share (%) Distribution of CLBP by Therapies in 2032

4 Epidemiology and Market Methodology of CLBP

5 Executive Summary of Chronic Lower Back Pain (CLBP)

6 Key Events

7 Chronic Low Back pain (CLBP): Disease Background and Overview

7.1 Introduction

7.2 Signs and Symptoms

7.3 Causes and Risk Factors

7.4 Genetics of Chronic Lower Back Pain

7.5 Pathophysiology

7.6 Types of Pain

7.7 Diagnosis

7.7.1 AAPT Diagnostic Criteria for CLBP

7.7.2 Test for CLAB diagnosis

7.7.3 Imaging Guidelines

7.8 Treatment and Management

7.8.1 Treatment Approaches

7.8.2 Treatment Algorithm

7.8.3 Proposed Guidelines for Chronic Lower Back Pain

7.8.3.1 NICE Guidelines

7.8.3.2 Center for Disease Control and Prevention (CDC) Guidelines

7.8.3.3 American College of Physicians (ACP) Guidelines

7.8.3.4 WHO Guideline for Nonsurgical Management of Chronic Primary Low Back Pain in Adults in Primary and Community Care Settings

7.8.3.5 Interventions for the Management of Acute and Chronic Low Back Pain (Revision 2021): American Physical Therapy Association (APTA)

7.8.3.6 VA/DoD Clinical Practice Guidelines: Diagnosis and Treatment of Low Back Pain (LBP) (2023)

7.8.3.7 Chronic Low Back Pain: A Narrative Review of Recent International Guidelines for Diagnosis and Conservative Treatment

8 Epidemiology and Patient Population

8.1 Key Findings

8.2 Assumptions and Rationale: The 7MM

8.3 Total Prevalent Cases of CLBP in the 7MM

8.4 Total Diagnosed Prevalent Cases of CLBP in the 7MM

8.5 The United States

8.5.1 Total Prevalent Cases of CLBP in the United States

8.5.2 Total Diagnosed Prevalent Cases of CLBP in the United States

8.5.3 Gender-specific Diagnosed Prevalent Cases of CLBP in the United States

8.5.4 Age-specific Diagnosed Prevalent Cases of CLBP in the United States

8.6 EU4 and the UK

8.6.1 Germany

8.6.1.1 Total Prevalent Cases of CLBP in Germany

8.6.1.2 Total Diagnosed Prevalent Cases of CLBP in Germany

8.6.1.3 Gender-specific Diagnosed Prevalent Cases of CLBP in Germany

8.6.1.4 Age-specific Diagnosed Prevalent Cases of CLBP in Germany

8.6.2 France

8.6.2.1 Total Prevalent Cases of CLBP in France

8.6.2.2 Total Diagnosed Prevalent Cases of CLBP in France

8.6.2.3 Gender-specific Diagnosed Prevalent Cases of CLBP in France

8.6.2.4 Age-specific Diagnosed Prevalent Cases of CLBP in France

8.6.3 Italy

8.6.3.1 Total Prevalent Cases of CLBP in Italy

8.6.3.2 Total Diagnosed Prevalent Cases of CLBP in Italy

8.6.3.3 Gender-specific Diagnosed Prevalent Cases of CLBP in Italy

8.6.3.4 Age-specific Diagnosed Prevalent Cases of CLBP in Italy

8.6.4 Spain

8.6.4.1 Total Prevalent Cases of CLBP in Spain

8.6.4.2 Total Diagnosed Prevalent Cases of CLBP in Spain

8.6.4.3 Gender-specific Diagnosed Prevalent Cases of CLBP in Spain

8.6.4.4 Age-specific Diagnosed Prevalent Cases of CLBP in Spain

8.6.5 The UK

8.6.5.1 Total Prevalent Cases of CLBP in the UK

8.6.5.2 Total Diagnosed Prevalent Cases of CLBP in the UK

8.6.5.3 Gender-specific Diagnosed Prevalent Cases of CLBP in the UK

8.6.5.4 Age-specific Diagnosed Prevalent Cases of CLBP in the UK

8.7 Japan

8.7.1 Total Prevalent Cases of CLBP in Japan

8.7.2 Total Diagnosed Prevalent Cases of CLBP in Japan

8.7.3 Gender-specific Diagnosed Prevalent Cases of CLBP in Japan

8.7.4 Age-specific Diagnosed Prevalent Cases of CLBP in Japan

9 Patient Journey

10 Marketed Drugs

10.1 Key Cross Competition

10.2 XTAMPZA ER (oxycodone): Collegium Pharmaceutical

10.2.1 Product Description

10.2.2 Regulatory Milestones

10.2.3 Other Developmental Activities

10.2.4 Clinical Trials Information

List to be continued in the report…

11 Emerging Therapies

11.1 Key Cross Competition

11.2 Rexlemestrocel-L (MPC-06-ID): Mesoblast Limited/Grünenthal

11.2.1 Product Description

11.2.2 Other Developmental Activities

11.2.3 Clinical Trials Information

11.2.4 Safety and Efficacy

11.2.5 Analyst Views

11.3 SEMDEXA (SP-102): Scilex Holding Company

11.3.1 Product Description

11.3.2 Other Developmental Activities

11.3.3 Clinical Trials Information

11.3.4 Safety and Efficacy

11.3.5 Analyst Views

To be continued in the report

12 Chronic Lower Back Pain: Seven Major Market Analysis

12.1 Key Findings: Market

12.2 Key Market Forecast Assumptions

12.3 Conjoint Analysis

12.4 Market Outlook

12.5 Market Size of CLBP in the 7MM

12.6 Market size of CLBP by Therapies in the 7MM

12.7 Market Size of CLBP in the United States

12.7.1 Total Market Size of CLBP in the United States

12.7.2 Market Size by Therapies in the US

12.8 Market Size of CLBP in EU4 and the UK

12.8.1 Germany

12.8.1.1 Total Market Size of CLBP

12.8.1.2 Market Size of CLBP by Therapies

12.8.2 France

12.8.2.1 Total Market Size of CLBP

12.8.2.2 Market Size of CLBP by Therapies

12.8.3 Italy

12.8.3.1 Total Market Size of CLBP

12.8.3.2 Market Size of CLBP by Therapies

12.8.4 Spain

12.8.4.1 Total Market Size of CLBP

12.8.4.2 Market Size of CLBP by Therapies

12.8.5 The United Kingdom

12.8.5.1 Total Market Size of CLBP

12.8.5.2 Market Size of CLBP by Therapies

12.9 Japan Market Size

12.9.1 Total Market Size of CLBP in Japan

12.9.2 Market Size of CLBP by Therapies

13 KOL Views

14 SWOT Analysis

15 Unmet Needs

16 Reimbursement and Market Access

17 Appendix

18 Bibliography

19 Report Methodology

19.1 DRA Capabilities

19.2 Disclaimer

20 About DRA